Home » Stocks » AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. (ACRX)

Stock Price: $1.12 USD 0.03 (2.75%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 90.46M
Revenue (ttm) 2.41M
Net Income (ttm) -55.49M
Shares Out 80.76M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $1.12
Previous Close $1.09
Change ($) 0.03
Change (%) 2.75%
Day's Open 1.14
Day's Range 1.10 - 1.15
Day's Volume 1,177,621
52-Week Range 0.70 - 2.80

More Stats

Market Cap 90.46M
Enterprise Value 67.90M
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 80.76M
Float 79.56M
EPS (basic) -0.7
EPS (diluted) -0.70
FCF / Share -0.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.29M
Short Ratio 12.84
Short % of Float 14.82%
Beta 1.81
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 37.53
PB Ratio n/a
Revenue 2.41M
Operating Income -57.74M
Net Income -55.49M
Free Cash Flow -55.19M
Net Cash 22.55M
Net Cash / Share 0.28
Gross Margin -380.83%
Operating Margin -2,395.64%
Profit Margin -2,302.50%
FCF Margin -2,290.00%
ROA -36.65%
ROE n/a
ROIC -63.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(412.50% upside)
Current: $1.12
Target: 5.74
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth6.42%-73.1%-53.94%-9.89%269.24%-82.32%1132.33%123.32%--
Gross Profit-4.52-1.83-2.665.0417.495.2229.502.391.07-
Operating Income-54.21-35.73-38.68-31.96-19.95-37.65-6.67-29.71-19.35-12.19
Net Income-53.24-47.15-51.51-43.16-24.40-33.35-23.43-33.36-20.10-14.34
Shares Outstanding79.1858.4146.8845.3144.3043.4339.7522.1217.340.66
Earnings Per Share-0.67-0.81-1.10-0.95-0.60-0.91-0.59-1.51-1.16-21.84
Operating Cash Flow-51.18-29.08-29.77-29.40-19.95-34.46-0.49-24.58-15.29-12.23
Capital Expenditures-3.47-0.82-2.41-3.72-1.46-5.51-3.29-0.83-2.02-
Free Cash Flow-54.65-29.89-32.17-33.12-21.41-39.96-3.77-25.41-17.31-12.23
Cash & Equivalents66.1410660.6580.4911475.6010459.9735.993.89
Total Debt29.7611.9919.1021.5520.9224.8714.3615.9719.0812.01
Net Cash / Debt36.3893.7241.5558.9492.7250.7389.5544.0016.91-8.12
Book Value-41.424.25-36.51-5.3433.1146.6673.1633.8517.47-65.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AcelRx Pharmaceuticals, Inc.
Country United States
Employees 59
CEO Vincent J. Angotti

Stock Information

Ticker Symbol ACRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ACRX
IPO Date February 14, 2011


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.